

Mangesh A Thorat

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1760151/mangesh-a-thorat-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86 papers	10,198 citations	26 h-index	100 g-index
104 ext. papers	12,616 ext. citations	10 avg, IF	5.5 L-index

#	Paper	IF	Citations
86	STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. <i>Annals of Medicine and Surgery</i> , 2021 , 72, 103026	2	27
85	Delivering brief physical activity interventions in primary care: a systematic review. <i>British Journal of General Practice</i> , 2021 ,	1.6	2
84	STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. <i>International Journal of Surgery Open</i> , 2021 , 100430	0.9	22
83	STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. <i>International Journal of Surgery</i> , 2021 , 96, 106165	7.5	147
82	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. <i>The Cochrane Library</i> , 2021 , 10, CD013091	5.2	2
81	Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma : Results from the UK/ANZ DCIS Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 2861-2867	12.9	4
80	Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma : Results from the UK/ANZ DCIS Randomized Trial. <i>Clinical Cancer Research</i> , 2021 ,	12.9	3
79	Breast cancer prevention in high-risk women. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020 , 65, 18-31	4.6	44
78	The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasESeries in Surgery (PROCESS) Guidelines. <i>International Journal of Surgery</i> , 2020 , 84, 231-235	7.5	254
77	The SCARE 2020 Guideline: Updating Consensus Surgical Case REport (SCARE) Guidelines. <i>International Journal of Surgery</i> , 2020 , 84, 226-230	7.5	2300
76	WITHDRAWAL-Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe. <i>Tumori</i> , 2020 , 106, NP2-NP4	1.7	0
75	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz049	4.6	4
74	Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings. <i>Breast Cancer Research</i> , 2019 , 21, 114	8.3	10
73	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz050	4.6	6
72	STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. <i>International Journal of Surgery</i> , 2019 , 72, 156-165	7.5	855
71	Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study. <i>Clinical Breast Cancer</i> , 2019 , 19, e116-e126	3	13
70	Aspirin and Cancer 2018 , 85-85		

69	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. <i>The Cochrane Library</i> , 2018 ,	5.2	1
68	The PROCESS 2018 statement: Updating Consensus Preferred Reporting Of Case Series in Surgery (PROCESS) guidelines. <i>International Journal of Surgery</i> , 2018 , 60, 279-282	7.5	316
67	The SCARE 2018 statement: Updating consensus Surgical Case Report (SCARE) guidelines. <i>International Journal of Surgery</i> , 2018 , 60, 132-136	7.5	1971
66	Assessing opportunities for coordinated R&D in early cancer detection and management in Europe. <i>International Journal of Cancer</i> , 2017 , 140, 1700-1701	7.5	1
65	The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. <i>International Journal of Surgery</i> , 2017 , 46, 198-202	7.5	662
64	Preventing invasive breast cancer using endocrine therapy. <i>Breast</i> , 2017 , 34 Suppl 1, S47-S54	3.6	13
63	Preferred reporting of case series in surgery; the PROCESS guidelines. <i>International Journal of Surgery</i> , 2016 , 36, 319-323	7.5	311
62	A major flaw in "Awareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population based survey". <i>Maturitas</i> , 2016 , 88, 45	5	
61	Abstract P3-07-02: Prognostic and predictive relevance of HER2 status in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial 2016 ,		2
60	Individualised benefit-harm balance of aspirin as primary prevention measure - a good proof-of-concept, but could have been better <i>BMC Medicine</i> , 2016 , 14, 101	11.4	2
59	The SCARE Statement: Consensus-based surgical case report guidelines. <i>International Journal of Surgery</i> , 2016 , 34, 180-186	7.5	1507
58	Reply to the letter to the editor The harms of low-dose aspirin prophylaxis are overstated by P. Elwood and G. Morgan. <i>Annals of Oncology</i> , 2015 , 26, 442-3	10.3	1
57	Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. <i>European Journal of Epidemiology</i> , 2015 , 30, 5-18	12.1	47
56	Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK. <i>International Journal of Surgery Case Reports</i> , 2015 , 16, 77-80	0.8	10
55	Estimates of benefits and harms of prophylactic use of aspirin in the general population. <i>Annals of Oncology</i> , 2015 , 26, 47-57	10.3	241
54	Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. <i>Ecancermedicalscience</i> , 2015 , 9, 595	2.7	17
53	Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. <i>Breast</i> , 2015 , 24 Suppl 2, S51-5	3.6	28
52	Performance of the Xpert HPV assay in women attending for cervical screening. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015 , 1, 32-37	4.6	26

51	PSA testing for prostate cancer screening--authorsPreply. <i>Lancet Oncology, The</i> , 2015 , 16, e3	21.7	0
50	Prevention and early detection of prostate cancer. <i>Lancet Oncology, The</i> , 2014 , 15, e484-92	21.7	277
49	DNA methylation gene-based models indicating independent poor outcome in prostate cancer. <i>BMC Cancer</i> , 2014 , 14, 655	4.8	15
48	Role of aspirin in cancer prevention. <i>Current Oncology Reports</i> , 2013 , 15, 533-40	6.3	72
47	Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 35-40	6.2	27
46	FOXP3 expression and nodal metastasis of breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2013 , 36, 405-9	7.2	5
45	Tackling breast cancer in India. <i>Lancet, The</i> , 2012 , 379, 2340-1	4.0	
44	Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. <i>Cancer Biomarkers</i> , 2012 , 11, 75-88	3.8	12
43	13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 505-505	2.2	6
42	Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer Using Pyrosequencing. <i>Disease Markers</i> , 2011 , 30, 151-161	3.2	70
41	The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 797-802	4.4	90
40	Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. <i>Disease Markers</i> , 2011 , 30, 151-61	3.2	47
39	Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet. <i>Cancer Research</i> , 2010 , 70, 685-96	10.1	22
38	ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2010 , 10, 600-14	4.6	12
37	Loss of ER α and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. <i>Oncology Reports</i> , 2010 , 24, 1233-9	3.5	19
36	Role of glucocorticoids in breast cancer. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3593-600	3.3	19
35	Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. <i>Modern Pathology</i> , 2010 , 23, 270-5	9.8	41
34	Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. <i>American Journal of Pathology</i> , 2010 , 176, 2139-49	5.8	36

33	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 97-108	4.4	148
32	Differential subcellular expression of protein kinase C beta11 in breast cancer: correlation with breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 327-35	4.4	12
31	VEGFA amplification/deletion in human breast tumors.. <i>Journal of Clinical Oncology</i> , 2010 , 28, e21017-e21017	2	
30	COX-2 expression does not correlate with microvessel density in breast cancer. <i>Pathobiology</i> , 2009 , 76, 39-44	3.6	4
29	Differential gene expression profiling of esophageal adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009 , 137, 829-34	1.5	10
28	Comment on "Dynamic response to heat--a novel physical characteristic of breast cancer". <i>International Journal of Surgery</i> , 2009 , 7, 173	7.5	
27	Prostanoid receptor EP1 expression in breast cancer. <i>Modern Pathology</i> , 2008 , 21, 15-21	9.8	25
26	Amplified in breast cancer 1 expression in breast cancer. <i>Histopathology</i> , 2008 , 53, 634-41	7.3	9
25	MRI breast screening. <i>Lancet, The</i> , 2008 , 371, 1415; author reply 1416	40	
24	Five genetic variants associated with prostate cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 2738; author reply 2741	59.2	5
23	Revision surgery for breast cancer: single-institution experience. <i>Cancer</i> , 2008 , 113, 2347-52	6.4	13
22	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. <i>Journal of Clinical Pathology</i> , 2008 , 61, 327-32	3.9	87
21	Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts). <i>Journal of Clinical Oncology</i> , 2008 , 26, 1019-1019	2.2	5
20	Radiation therapy for ductal carcinoma in situ: is it really worth it?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 461-2; author reply 462	2.2	5
19	FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. <i>Clinical Cancer Research</i> , 2007 , 13, 4415-21	12.9	187
18	Uptake characteristics of FDG in multiple juvenile cellular fibroadenomata of the breast: FDG-PET and histopathologic correlation. <i>Clinical Nuclear Medicine</i> , 2007 , 32, 203-4	1.7	8
17	Prognostic factors in invasive breast carcinoma: Do new molecular techniques/profiling add significantly to traditional histological factors?. <i>Current Diagnostic Pathology</i> , 2007 , 13, 116-125		
16	Gene-signature-based prognostic tools in breast cancer: not yet. <i>Lancet, The</i> , 2007 , 369, 1428	40	1

15	Should we undertake an MRI breast screening trial?. <i>Lancet, The</i> , 2007 , 370, 1902; author reply 1903-4	40	2
14	Developing countries: an evolving opportunity for oncologic research. <i>World Journal of Surgery</i> , 2006 , 30, 1173-6	3.3	
13	Trastuzumab for early breast cancer. <i>Lancet, The</i> , 2006 , 367, 108	40	1
12	Medical research in India. <i>Lancet, The</i> , 2006 , 368, 643-4	40	1
11	Are there distinct lymphatic flow patterns in the Breast?. <i>Medical Hypotheses</i> , 2006 , 66, 1040-1	3.8	2
10	Tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, E1-E1		
9	Tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, E1		4
8	Cancer immunotherapeutics: raising the ante. <i>The National Medical Journal of India</i> , 2006 , 19, 140-50	0.4	
7	Does primary tumor location have prognostic significance in operable breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 396-7		
6	Autoantibodies in prostate cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 2815-7; author reply 2815-7	59.2	3
5	Herceptin in early breast cancer: a call for judicious use. <i>The National Medical Journal of India</i> , 2005 , 18, 315-7	0.4	
4	Optimum cancer care--an unaffordable goal?. <i>Lancet Oncology, The</i> , 2004 , 5, 529-30	21.7	5
3	Optimum cancer care--an unaffordable goal?. <i>Lancet Oncology, The</i> , 2004 , 5, 530	21.7	1
2	Sentinel-node biopsy in breast cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 1968-71; author reply 1968-71	59.2	11
1	Radical and simple mastectomy. <i>New England Journal of Medicine</i> , 2002 , 347, 2170-1; author reply 2170-1	59.2	